CNR1 and obesity due to melanocortin 4 receptor deficiency: The demand for a therapy to counteract obesity, combined with multiple other beneficial effects on plasma triglyceride levels, fasting insulin and glucose levels, and β-cell function in diabetes, has led to the search for peripherally restricted CB1R antagonists4, 7.